StockNews.AI
EBS
StockNews.AI
182 days

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

1. EBS will host a earnings call on March 3, 2025. 2. Company plans to present at J.P. Morgan’s Finance Conference. 3. The earnings call will cover Q4 and full year 2024 results. 4. Emergent's mission focuses on public health threat solutions.

4m saved
Insight
Article

FAQ

Why Neutral?

Earnings calls usually have minimal immediate effects; context and results matter.

How important is it?

Financial results could affect stock performance and strategic investor sentiments.

Why Short Term?

Upcoming financial results may cause brief price activity but likely not lasting change.

Related Companies

EBS
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025 February 18, 2025 08:55 ET  | Source: Emergent BioSolutions GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be accessed from the Investors page of Emergent’s website. Additional Investor Event – Webcast InformationEmergent will also provide a brief presentation and remarks during J.P. Morgan’s 2025 Leveraged Finance Conference. Participants may access the presentation via webcast at 11:00 am eastern time on Monday, February 24, 2025. About Emergent BioSolutionsAt Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com   Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com

Related News